8-K: Bionano Genomics Implements 1-for-60 Reverse Stock Split to Boost Share Price

Bionano Genomics executed a 1-for-60 reverse stock split, effective January 24, 2025, to increase its stock price and maintain Nasdaq compliance.

Summary

• Bionano Genomics implemented a 1-for-60 reverse stock split, effective January 24, 2025, at 5:00 p.m. Eastern Time.
• The reverse stock split was approved by stockholders at a special meeting on January 15, 2025.
• Every 60 shares of issued and outstanding common stock were converted into one share.
• Proportionate adjustments were made to stock options, restricted stock units, and warrants.
• No fractional shares will be issued; stockholders will receive cash payments in lieu of fractional shares.
• The reverse stock split affects all stockholders proportionally and does not change percentage ownership (except for fractional shares).
• Trading on a split-adjusted basis began on January 27, 2025, on the Nasdaq Capital Market under the symbol BNGO.
• The new CUSIP number for the common stock is 09075F404.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the reverse stock split is a common corporate action, it's often a sign of underlying financial challenges. The company is taking steps to remain compliant with Nasdaq listing requirements, but the long-term impact is uncertain.

Positives

• The reverse stock split is intended to increase the market price of Bionano's common stock.
• The reverse stock split should assist Bionano in maintaining compliance with Nasdaq listing requirements.
• Existing shareholders' proportional ownership remains the same, except in the case of fractional shares.

Negatives

• The reverse stock split reduces the number of outstanding shares of common stock.
• The reverse stock split reduces the number of shares issuable upon conversion of convertible debentures and exercise/vesting of stock options, restricted stock units and warrants.
• The reverse stock split increases the conversion and exercise prices of convertible debentures, stock options, restricted stock units and warrants.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• Adverse geopolitical and macroeconomic events could impact Bionano's business and the global economy.
• Failure to drive adoption of optical genome mapping could negatively impact the company.
• The company's ability to continue as a going concern depends on managing costs and obtaining additional financing.
• Failure to cure deficiencies in compliance with Nasdaq Listing Rules could adversely affect the company's ability to raise capital.

Future Outlook

The company expects the reverse stock split to increase the market price of its common stock and maintain compliance with Nasdaq listing requirements.

Management Comments

• Bionano announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-60.

Industry Context

Reverse stock splits are often used by companies facing delisting from exchanges due to low share prices, or to make their stock more attractive to institutional investors.

Comparison to Industry Standards

• Other companies in the biotech industry, such as Celldex Therapeutics and VBI Vaccines, have also implemented reverse stock splits to maintain listing compliance and improve stock price.
• The 1-for-60 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-100 or more.

Stakeholder Impact

• Stockholders will see a reduction in the number of shares they own, but their percentage ownership will remain the same (except for fractional shares).
• Employees holding stock options or restricted stock units will see adjustments to the number of shares and exercise prices.
• The reverse stock split may improve investor perception of the company.

Next Steps

• Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split.
• The company's transfer agent, Equiniti Trust Company, LLC, will act as exchange agent for the reverse stock split.

Key Dates